GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
The DOI matches its Crossref record; 54 of the 56 references it cites were found in a registry or an index.
Abstract
Gut-derived hormones, such as GLP-1, have been proposed to relay information to the brain to regulate appetite. GLP-1 receptor agonists, currently used for the treatment of type 2 diabetes (T2DM), improve glycemic control and stimulate satiety, leading to decreases in food intake and body weight. We hypothesized that food intake reduction after GLP-1 receptor activation is mediated through appetite- and reward-related brain areas. Obese T2DM patients and normoglycemic obese and lean individuals (n = 48) were studied in a randomized, crossover, placebo-controlled trial. Using functional MRI, we determined the acute effects of intravenous administration of the GLP-1 receptor agonist exenatide, with or without prior GLP-1 receptor blockade using exendin 9-39, on brain responses to food pictures during a somatostatin pancreatic-pituitary clamp. Obese T2DM patients and normoglycemic obese versus lean subjects showed increased brain responses to food pictures in appetite- and reward-related brain regions (insula and amygdala). Exenatide versus placebo decreased food intake and food-related brain responses in T2DM patients and obese subjects (in insula, amygdala, putamen, and orbitofrontal cortex). These effects were largely blocked by prior GLP-1 receptor blockade using exendin 9-39. Our findings provide novel insights into the mechanisms by which GLP-1 regulates food intake and how GLP-1 receptor agonists cause weight loss.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1 reduces appetite and food intake through its actions in the CNS.212,260,261”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [212]
In the citing paper
“GLP-1RAs work via numerous mechanisms that contribute to weight loss, one of the most well-known of which is the gut-brain axis.212,213,390”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [212]
In the citing paper
“Incretin therapies work in the appetite and reward circuitries to modulate food intake and energy balance, reducing uncontrollable hunger, overeating, and bulimic symptoms (413), although mechanisms are not completely understood.”
From 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes:Standards of Care in Diabetes—2023 (2023) · cites this paper as [413]
Citations
Cites
IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040
Ogurtsova, K., da Rocha Fernandes, J. D., Huang, Y., Linnenkamp, U., Guariguata, L., Cho, N. H., Cavan, D., Shaw, J. E., & Makaroff, L. E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.03.024 · Cited by 6,966
Prevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010
Flegal, K. M., Carroll, M. D., Kit, B. K., & Ogden, C. L. (2012) · JAMA · doi:10.1001/jama.2012.39 · Cited by 5,385 · cited 1×
“The global rise in obesity and type 2 diabetes (T2DM) prevalence is a major public health problem (1,2).”
BackgroundIDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
Whiting, D. R., Guariguata, L., Weil, C., & Shaw, J. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.029 · Cited by 3,994
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“GLP-1 stimulates meal-related insulin secretion, inhibits glucagon release, and delays gastric emptying, mechanisms that all contribute to its glucometabolic effects (11).”
BackgroundDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“The weight reduction seen during GLP-1 receptor agonist treatment is also observed in the absence of nausea (47).”
BackgroundGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“In contrast to previous studies (50), we found no statistically significant effects of GLP-1 receptor activation on scores of hunger, fullness, appetite, prospective food consumption, and desire to eat.”
ResultBaxter, M. G., & Murray, E. A. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn875 · Cited by 1,200 · cited 1×
“The amygdala plays a pivotal role in emotional learning and in the association of cues with reward (33) by encoding the value of the reward predicted by the conditioned stimuli (34).”
BackgroundChanges in brain activity related to eating chocolate: From pleasure to aversion
Small, D. M. (2001) · Brain · doi:10.1093/brain/124.9.1720 · Cited by 1,179 · cited 4×
“The insula is involved in the processing of food-cues and craving for food (31) and has been implicated in the devaluation of food-cues when eating to satiety (32).”
BackgroundInfluentialDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 3×
“A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.”
BackgroundMethodVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 6×
“Interestingly, GLP-1-receptor agonists have shown modest but consistent weight loss in humans (14).”
BackgroundResultInfluential
Research works printed but not linked: 1
- Wald, 1990, The shortened version of the Dutch translation of the Profile of Mood States (POMS), Ned Tijdschr Psychol, 45, 86
Cited by
Items 401–498 of 498
Richardson, R. (2019) · Nottingham ePrints (University of Nottingham) · doi:10.26180/5cb56665b5dbd
“Liranglutide, a glucagon-like 8 peptide-1 (GLP-1) analogue that acts as an agonist at the GLP receptor family resulting in satiety and reduced food intake (Van Bloemendaal et al., 2014).”
BackgroundIntestinal Enteroendocrine Disorders in the Fetus and Neonate
Yang, J. S., Jonnakuti, V. S., Stanescu, D. E., & León, D. D. D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814823-5.00047-7
The role of blocking serotonin 2C receptor by fluoxetine in the treatment of bulimia
Krzystanek, M., & Pałasz, A. (2020) · Pharmacotherapy in Psychiatry and Neurology · doi:10.33450/fpn.2020.07.001
Nolde, J. M., Connor, S. G., Al-Zubaidi, A., Obst, M. A., Laupenmühlen, J., Heldmann, M., Jauch‐Chara, K., & Münte, T. F. (2021) · Comprehensive Psychoneuroendocrinology · doi:10.1016/j.cpnec.2021.100055
Glucagon‐Like Peptide‐1 Receptor Activators
Wagner, M., Evers, A., Bossart, M., & Konkar, A. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc268
Xiao, S., Yang, Y., Liu, Y., & Zhu, J. (2021) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-021-00974-0
The Endocrine Regulation of Energy and Body Weight
Preiato, V. L., Vicennati, V., Gambineri, A., & Pagotto, U. (2016) · Endocrinology · doi:10.1007/978-3-319-27318-1_22-1
Advances in Pharmacological Treatment of Pediatric Obesity
Goran, M. I. (2016) · CRC Press eBooks · doi:10.1201/9781315370958-31
Prevention and Treatment of Childhood Obesity and Metabolic Syndrome
Roy, S. M., Rustico, S. E., & Kublaoui, B. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-11251-0_46
Food Reward and Appetite Regulation in Children
Goran, M. I. (2016) · CRC Press eBooks · doi:10.1201/9781315370958-10
Geary, N., & Asarian, L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.03942-8
Kanamarlapudi, V. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734616040.793572407
Regulation von Hunger, Sättigung und Stoffwechsel durch gastrointestinale Hormone
Roth, C. L., & Reinehr, T. (2022) · Springer eBooks · doi:10.1007/978-3-662-59216-8_17
DDS Perspective: Time to Get Serious About the Global Pandemic
Carr, R. M. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07628-z
Clinical Potential of Glucagon-like Peptide-1 Analogs in the Management of Diabesity
Sharma, N., & Singh, S. (2023) · Journal of Diabetology · doi:10.4103/jod.jod_102_22
Incretin Therapies: Current Use and Emerging Possibilities
Schlögl, H., & Stümvoll, M. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_35
Chiappini, S., Vickers‐Smith, R., Harris, D. R., Papanti, D., Corkery, J., Guirguis, A., Martinotti, G., Sensi, S. L., & Schifano, F. (2023) · Preprints.org · doi:10.20944/preprints202309.1300.v1
Régulation et fonctions du facteur de transcription ChREBP dans l'épithélium intestinal
Charifi, W. (2021) · theses.fr (ABES) · doi:10.70675/89543c3fz31abz4d56zaa7bz77c2c07ffd69
Brain-based Etiology of Weight RegulationPreprint
Burger, K. S., & Sadler, J. R. (2017) · NutriXiv (OSF Preprints) · doi:10.31232/osf.io/yq2cz_v1
Effects of Sugars and Non-Nutritive Sweeteners on Neural and Endocrine Regulation of Eating Behavior
Page, K. A. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197688908.003.0006
GLP-1 Agonists Can Be Heaven or Hell Dependent Upon Dopaminergic Genetic/Epigenetic AntecedentsPreprint
Mahajan, Y., Mahajan, S., Sharafshah, A., Sunder, K. R., Lewandrowski, K., Mohankumar, K., Lorio, M. P., Dowling, Á., Dowling, R., Bergamaschi, J. P. M., et al. (2025) · Preprints.org · doi:10.20944/preprints202510.1849.v1
Intestinal Enteroendocrine Disorders in the Fetus and Neonate
Rubenstein, A., & León, D. D. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-23940-3.00028-4
Bremmer, M. P., Courtney, J. B., Neilson, A. P., Burger, K. S., Thiele, T. E., & Hendershot, C. S. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06980-y
Kapan, A., Haider, S., Moser, O., Waldhoer, T., & Felsinger, R. (2025) · Obesity Facts · doi:10.1159/000550051
Jensterle, M., Ferjan, S., Battelino, T., Kovač, J., Battelino, S., Šuput, D., Vovk, A., & Janež, A. (2021) · Figshare · doi:10.6084/m9.figshare.15020783
A human laboratory model of alcohol satiety and the role of glucagon-like peptide 1
Bremmer, M. P. (2025) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/17n3-n065
Jensterle, M., Ferjan, S., Battelino, T., Kovač, J., Battelino, S., Šuput, D., Vovk, A., & Janež, A. (2021) · Figshare · doi:10.6084/m9.figshare.15020780
Krajnc, N., Itariu, B. K., Macher, S., Marik, W., Harreiter, J., Michl, M., Novak, K., Wöber, C., Pemp, B., & Bsteh, G. (2023) · Figshare · doi:10.6084/m9.figshare.23700431
New avenues for GLP1 receptor agonists in the treatment of diabetes
Sedman, T. (2021) · DSpace repository (University of Tartu)
Nafisi, R. (2024) · oURspace (University of Regina) · doi:10.82465/5170
ELSAYED, A. M. I., & アーメド, モ. (2022) · Institutional Repositories DataBase (IRDB)
GLP-1-secreting L-cell signalling in response to Bifidobacterium breve ncfb2258
Adewale, L. (2024) · DiVA (Digitala Vetenskapliga Arkivet)
Impatto del calo ponderale ottenuto tramite chirurgia bariatrica su GLP-1 e neuroplasticità in vivo
BONANINI, M. (2017) · Electronic Theses and Dissertations Repository (University of Pisa)
Relevancia motivacional de los estímulos relacionados con la comida y el cuerpo en bulimia nerviosa
Hernández-Rivero, I. (2021) · Institutional Repository of the University of Granada (University of Granada)
Farmácia Pipa, Braga e Serviços Farmacêuticos da Univerzitná Nemocnica Martin Hospital, Eslováquia
Brandão, L. O. D. A. (2022) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/pdxh-n866
The mediterranean diet in metabolic syndrome
Παππά, Χ. Γ., & Παππά, Χ. Γ. (2025) · University of Thessaly Institutional Repository (University of Thessaly)
Sraboni, A., Farhana, K. M., & Abdul, M. K. (2026) · Journal of Biotechnology and Food Engineering · doi:10.64907/xkmf.v4.i1.jbfe.1
Navigating the Psychosocial Aspects in Diabetes
Moverley, J., & Huynh, P. (2026) · Physician Assistant Clinics · doi:10.1016/j.cpha.2025.11.004
Vieira, I. C. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Neuropsychiatrische Effekte von GLP-1-Rezeptor-Agonisten
Spranger, S. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01438-x
Understanding Semaglutide’s weight- loss efficacy: A review of GLP- 1 biology
Mohammad, A. J., Kanaparthi, M., Dovari, H., Syed, N., Bellapu, D., & Kantamaneni, P. (2026) · International Journal of Pharmacology and Clinical Research · doi:10.33545/26647613.2026.v8.i2a.194
Inkeller, J. (2025) · Pesci Egyetemi Archivum (University of Pécs)
Gill, H. (2025) · TSpace (University of Toronto)
Role of the neonatal intestinal microbiota in the eating behaviour programming in rat
Pocheron, A.-L. (2019) · theses.fr (ABES)
Koide, Y. (2026) · Institutional Repositories DataBase (IRDB)
Trabelsi, M.-S. (2015) · theses.fr (ABES) · doi:10.70675/57d5cdf4z352ez4ac4z9da1zee3dcc8aba01
“De plus, des résultats récents montrent également une inhibition de la prise alimentaire et de la réponse cérébrale à des stimuli visuels par l’Exendin-4 chez des patients diabétiques de type 2 et chez des patients obèses (van Bloemendaal et al. 2014). iii.”
BackgroundPocheron, A.-L. (2019) · theses.fr (ABES) · doi:10.70675/29969b86z2649z4b67zb315za23a1106f4ef
Mechanism of GLP-1 Receptor Agonists in Weight Loss through Appetite Suppression
姚, 张. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1641386
Rivera-Hernández, A. D. J., Gaspar-Rodríguez, A. D. J., & Zurita‐Cruz, J. N. (2026) · Boletín Médico del Hospital Infantil de México · doi:10.24875/bmhim.25000042
Stenlid, R., Cerenius, S. Y., Torbahn, G., Aydın, B. K., Ciba, I., Vilén, H., Mörwald, K., Geiersberger, S., Roomp, K., Cadamuro, J., et al. (2026) · Obesity Facts · doi:10.1159/000552826
“Indeed, functional MRI studies on adults with obesity and T2DM treated with exenatide showed decreased responses to food in the insula, amygdala, putamen, and orbitofrontal cortex [31].”
GLP 1 RECEPTOR AGONISTS AND THEIR EFFECTS ON REWARD AND COMPULSIVE BEHAVIORS
Pieńkowska, A., Malon, P., Śliwa, K., Trojańska, A., Geworkian, N., Hariasz, N., Pietz, M., & Szymańska, A. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4826
GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists
Abid, M., Sheikh, K. S., Ahmad, M. S., & Jiang, H. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s566414
OPTIONS AND LIMITATIONS OF OBESITY TREATMENT WITH GLP-1 RECEPTOR AGONISTS
Babíková, K. (2026) · Ateroskleróza · doi:10.33542/ate2026-12-6
Rivera-Hernández, A. D. J., Gaspar-Rodríguez, A. D. J., & Zurita‐Cruz, J. N. (2026) · Boletín Médico Del Hospital Infantil de México (English Edition) · doi:10.24875/bmhime.m25000122
Arantes, F. L. (2026) · International Journal of Latin American Religions · doi:10.1007/s41603-026-00345-9
Surgery on Patients Taking Glucagon-Like Peptide-1 Receptor Agonists
Rosen, C. B., & Gee, D. W. (2026) · Advances in Surgery · doi:10.1016/j.yasu.2026.03.011
Ozempic and thin line between therapy and dependence
Maheen, T., & Sohail, U. (2026) · Journal of the Pakistan Medical Association · doi:10.47391/jpma.32369
Mills, A. M., & Noble, E. E. (2026) · Appetite · doi:10.1016/j.appet.2026.108729
A Pragmatic Outpatient Framework for Appetite‐Related Phenotyping in Obesity
Velazquez-Navarro, J. A., Rodríguez‐Moriel, R., Márquez-Herrera, R. M., & Ramos‐Márquez, L. A. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70184
“This is consistent with current models of appetite regulation, in which homeostatic brain–gut signaling and reward‐related pathways interact to influence eating behavior [30].”
Gut–Brain–GLP-1 Axis Beyond Glycemic Control: Emerging Neuroprotective and Anti-Obesity Mechanisms
Kosey, S. (2026) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2026.18.555998
Zimmerman, E. A., & Shirani, A. (2026) · Springer eBooks · doi:10.1007/978-3-032-13040-2_3
He, W., Yi-di, S., Wang, X., He, S.-Y., Tao, X., Yuan, S.-X., Zhou, L., & Long, E.-W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1889594
Murugadoss, K., Venkatakrishnan, A., & Soundararajan, V. (2026) · npj Metabolic Health and Disease · doi:10.1038/s44324-026-00131-3
“…have established that the GLP-1 receptor plays important roles in hypothalamic homeostatic circuits, hindbraininteroceptivepathways,andreward-linkedstriatalsystems,while peripheraltissuessuchasheart,vasculature,gut,andendocrineorgansmay addadditionalon-targetorcontext-dependenteffects 10 – 17 .”
Kalafati, I. P., Krongauz, D. L., Bosco, A., Noto, A., Piras, C., Kafyra, M., Dessì, A., Mauri, M., Atzori, L., Weinberger, A., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70220
Gut-kidney signaling is impaired in individuals with type 2 diabetes
Mosterd, C. M., Wever, B. E., van Baar, M. J. B., Muskiet, M. H. A., van den Born, B. H., Nieuwdorp, M., Touw, D. J., Hoorn, E. J., Vogt, L., & van Raalte, D. H. (2026) · Clinical Kidney Journal · doi:10.1093/ckj/sfag315
“This regimen has previously been shown to achieve plasma exenatide concentrations within the therapeutic range (130–150 pg/ml) [ 21–23 ].”
Lu, D., Li, N., Yuan, Z., & Gao, Y. (2026) · Clinical Obesity · doi:10.1111/cob.70112
Desrochers, S. S., Li, R., & Flagel, S. B. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.08.750149
“Indeed, acute exenatide administration has been shown to reduce neural responses to food images (van Bloemendaal et al. 2014) and neural activity during the anticipation of a palatable food reward (van Bloemendaal et al. 2015).”
Brucar, L. R., Miller, K. M., & Volkow, N. D. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106990
“…individuals with obesity and obesity-T2DM, acute GLP-1RA-related changes in caloric intake positively correlated with GLP-1RA-induced changes in food cue activation in the insula, OFC, and caudate, whereas comparable associations were not observed in lean individuals (van Bloemendaal et al., 2014).”
InfluentialAlevizopoulos, A. G., Vasilakos, V., Kritikos, I., Alevizopoulou, M., Korompoki, E., Ψαλτοπούλου, Θ., & Paschou, S. Α. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261457548
Guirguis, A. (2026) · Cronfa (Swansea University)
Sorghum kombucha’s impact on lean pigs and obese pigs during early weight loss
Macaneiro, M. E. G. (2025) · K-State Research Exchange (Kansas State University)
Navya, M. (2025) · UPI Journal of Pharmaceutical Medical and Health Sciences
Biernat, P., Czerwińska, A., Cybulska, D., Cybulska, K., Morka, J., Sobczak, M., Wołyniec, E., & Kulpa, B. (2026) · African Journal of Biomedical Research · doi:10.69980/ajbr.v29i1s.9889
Novel Anti-Obesity Drugs: Pharmacokinetics, Pharmacodynamics, and Precision Dosing
Badawoud, A. M., Zaafar, D. K., AlRasheed, H. A., Aldossary, K. M., Alsharif, A. A., & Alsaleh, N. A. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00482-x
“Several studies have demonstrated that GLP-1 receptor agonists administration reduces activation in reward-related brain regions in response to high-calorie food cues, and the magnitude of this reduction correlates with the degree of weight loss [ 34].”
Endocrine responses to alcohol ingestion in women with and without metabolic surgery
Molina‐Castro, M. (2025) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
Ghosal, S. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100339
“Human neuroimaging and experimental studies further indicate that GLP-1 receptor activation can modify neural responses to food-related stimuli [23].”
InfluentialSemaglutide and Drug Craving: Emerging Perspectives in Addiction Psychiatry
Romeo, V. M. (2026) · JOURNAL OF MENTAL HEALTH AND CLINICAL PSYCHOLOGY · doi:10.29245/2578-2959/2026/3.1378
Food Noise in Obesity: Current Evidence, Measurement, and Clinical Implications
Ortiz-Martínez, Y. (2026) · Cureus · doi:10.7759/cureus.118095
Fagiolini, A. M., & Cuomo, A. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.10.039
Roslin, K., Andrews, R., Baella-Olivieri, B., & Roslin, M. S. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15218265
Stalpaert, S., Tanghe, A., Stremersch, E., Gies, I., Jean-Paul, T., Frederix, K., & Beauloye, V. (2026) · Belgian Journal of Paediatrics
Wajid, R., Kumar, R., Muneer, M., Ali, M. N., Mustafa, J. U., Qamar, J., Asif, D., Ziaulhaque, S., Sohail, I., Khamisani, F. A., et al. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02108-x
“GLP-1 receptor agonists reduce body weight through several complementary actions: central regulation of appetite through hypothalamic and reward pathways, increased satiety, reduced energy intake, and a slowing of gastric emptying [9, 18, 26].”
Pan, R., Wang, B., Li, Y., Li, H., Liang, X., Zhang, Y., Liu, X., Huang, X., Wang, R., Ji, H., et al. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s628886
Tang, H., Zhang, B., Lu, Y., Lu, Y., Wang, H., Davis, C. N., Kranzler, H. R., & Chen, Y. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71470
Zeng, S. R., Wu, L. Y., Ma, C. X., Zhang, X. F., Chen, W. L., Zhao, Y. T., Wang, J. X., Li, S. S., & Wang, L. H. (2026) · Journal of Endocrinology and Metabolism · doi:10.14740/jem1655
Obesity pharmacotherapies and cognition
Börchers, S., Mazzini, G., Zetterberg, H., & Clemmensen, C. (2026) · Science · doi:10.1126/science.aek9987
Camajani, E., Frigerio, F., Quattrini, C., Franzese, V., Armani, A., Gorini, S., Filardi, T., Feraco, A., Caprio, M., & Lombardo, M. (2026) · Nutrients · doi:10.3390/nu18213675
Disentangling semaglutide's effects on motivation in major depressive disorder: A mediation analysis
Gill, H., Badulescu, S., Shah, H., Brudner, R. M., Vincenzo, J. D. D., Tabassum, A., Phan, L., Teopiz, K. M., López, C.-D. L., Rosenblat, J. D., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122714
Six Challenges for a Mechanistic Science of Human Interoception
Avidan, G., Allen, M., Khalsa, S. S., Nord, C. L., Petzschner, F. H., & Rozenkrantz, L. (2026) · Journal of Neuroscience · doi:10.1523/jneurosci.1178-26.2026
Huang, J., Hua, F., Jiang, X., Zhang, X., Yang, M., Wang, L., Huang, X., & Luo, K. (2023) · doi:10.3389/fendo.2023.1130470.s001
Battini, V., Manen, R. P. V., Gringeri, M., Mosini, G., Guarnieri, G., Bombelli, A., Pozzi, M., Nobile, M., Radice, S., Clementi, E., et al. (2023) · doi:10.3389/fphar.2023.1128387.s003
Martinc, B. (2026) · Comprehensive physiology · doi:10.1002/cph4.70313
Metadata
- Authors
- van Bloemendaal, L., IJzerman, R. G., ten Kulve, J. S., Barkhof, F., Konrad, R. J., Drent, M. L., Veltman, D. J., & Diamant, M.
- Affiliations
- Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Eli Lilly (United States) (US)
- Amsterdam Neuroscience (NL)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-11-13
- Volume
- 63
- Issue
- 12
- Pages
- 4186-4196
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2018940614
- Cited by
- 427
- References
- 56
- Citations by year
- 2026: 52 · 2025: 60 · 2024: 44 · 2023: 39 · 2022: 25 · 2021: 35 · 2020: 28 · 2019: 25 · 2018: 22 · 2017: 30 · 2016: 34 · 2015: 29 · 2014: 4
- FWCI
- 15.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- VU Research Portal (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, exenatide, exendin-9-39, appetite regulation, food reward, food images, obesity, type 2 diabetes, satiety, insula, amygdala, orbitofrontal cortex, putamen, weight loss
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Adult, Aged, Amygdala, Appetite, Brain, Cerebral Cortex, Diabetes Mellitus, Type 2, Feeding Behavior, Female, Humans, Hypoglycemic Agents, Magnetic Resonance Imaging, Male, Middle Aged, Obesity, Peptide Fragments, Peptides, Photic Stimulation, Putamen, Reward, Venoms, Case-Control Studies, Prefrontal Cortex, Receptors, Glucagon, Cross-Over Studies, Functional Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.